RxDoctor Payments DataLook up a doctor →

Bart Sloan, MD

Psychiatry · Norwalk, CTNPI 1447282371

Payments from drug & device makers

$6,838,102in general payments, 2019–2025

Across 326 payments — averaging $20,976 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.3M
  • Genentech, Inc.$1.7M
  • Biogen$1.4M
  • Eisai Inc.$736K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$319K
  • Novo Nordisk AS$257K
  • plus $74K from 14 others
$17,781in research payments, 2019–2025

Across 4 payments — averaging $4445.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$18K

What the payments were for

  • Food & beverage$1,55097%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,838,102 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$132,801
Medicare patients
342
Services billed
1,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl27$43,197
Paliperidone ErPaliperidone85$19,215
TrintellixVortioxetine Hydrobromide22$14,418
AuvelityDextromethorphan Hbr/Bupropion14$12,989
Aripiprazole259$7,258
VyvanseLisdexamfetamine Dimesylate19$7,239
Quetiapine Fumarate458$7,183
Divalproex Sodium158$6,275
Risperidone427$5,190
Escitalopram Oxalate425$4,090
Fluoxetine Hcl338$4,053
Olanzapine255$3,974
Fluvoxamine Maleate97$3,885
Venlafaxine Hcl ErVenlafaxine Hcl84$3,679
RisperdalRisperidone13$3,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$398$43,19727 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$16,193$21,65741 claims
Johnson & JohnsonRisperdal$248$3,54013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in Norwalk

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →